表紙
市場調查報告書

市場聚光燈:冷血球凝集素症 (CAD)

Market Spotlight: Cold Agglutinin Disease

出版商 Datamonitor Healthcare 商品編碼 914885
出版日期 內容資訊 英文 23 Pages
商品交期: 最快1-2個工作天內
價格
市場聚光燈:冷血球凝集素症 (CAD) Market Spotlight: Cold Agglutinin Disease
出版日期: 2020年08月20日內容資訊: 英文 23 Pages
簡介

本報告提供全球冷血球凝集素症 (CAD) 治療藥市場相關調查分析,疾病的背景、治療資訊,主要開發平台藥物、臨床實驗,成功的概率,許可證、收購交易,流行病學概要相關的系統性資訊。

概要

要點

疾病的背景

  • 疾病定義
  • 患者的亞型
  • 症狀
  • 風險因素
  • 診斷

治療

  • 非藥物治療
  • 藥物治療

流行病學

開發平台藥物

成功的概率

許可證、資產取得交易

本源專利

臨床實驗形勢

  • 贊助商:各狀況
  • 贊助商:各階段

參考文獻

附錄

目錄
Product Code: DMKC0206674

This Market Spotlight report covers the Cold Agglutinin Disease market, comprising key pipeline drugs, clinical trials, probability of success, and an epidemiology overview.

Key Takeaways

There are only three industry-sponsored drugs in active clinical development for cold agglutinin disease, with one drug each in Phase I, Phase II, and the NDA/BLA phase.

Therapies in development for cold agglutinin disease target the complement pathway. These pipeline drugs are administered via the intraocular, subretinal, subconjunctival, intravenous, and subcutaneous routes.

The overall likelihood of approval of a Phase I autoimmune/immunology-other asset is 21.8%, and the average probability a drug advances from Phase III is 70.2%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.0 years in the overall autoimmune/immunology space.

The distribution of clinical trials across Phase I-III indicates that the majority of trials for cold agglutinin disease have been in the early and mid-phases of development, with 67% of trials in Phase I-II, and 33% in Phase III.

The majority of clinical trial activity in the cold agglutinin disease space comprises completed trials.

Sanofi leads industry sponsors with the highest number of clinical trials for cold agglutinin disease

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient subtypes
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Non-pharmacological treatment
  • Pharmacological treatment

EPIDEMIOLOGY

PIPELINE DRUGS

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for cold agglutinin disease in the US
  • Figure 2: Pipeline drugs for cold agglutinin disease, by company
  • Figure 3: Pipeline drugs for cold agglutinin disease, by drug type
  • Figure 4: Pipeline drugs for cold agglutinin disease, by classification
  • Figure 5: Probability of success in the cold agglutinin disease pipeline
  • Figure 6: Clinical trials in cold agglutinin disease
  • Figure 7: Top 10 drugs for clinical trials in cold agglutinin disease
  • Figure 8: Top 10 companies for clinical trials in cold agglutinin disease
  • Figure 9: Cold agglutinin disease trials status
  • Figure 10: Cold agglutinin disease trials sponsors, by phase

LIST OF TABLES

  • Table 1: Pipeline drugs for cold agglutinin disease in the US